Liang Yuan

Liang Yuan

Auto-generated profile, based on publicly available information

Liang Yuan

Blueprint Medicines Corporation, Cambridge, Massachusetts

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JRJiangong Ren
Jiangong Ren
CDCongxin Dai
Congxin Dai
XZXin Zhou
Xin Zhou
JBJoseph A. Barnes
Joseph A. Barnes
XCXi Chen
Xi Chen
JHJian Hu
Jian Hu
The mechanism underpinning the regulation of microglial phagocytosis in demyelinating diseases is unclear. Here, we showed that the Quaking protein (Qki) in microglia was greatly induced by demyelination in the brains of both mice and humans. Deletion of the Quaking gene (Qk) in microglia severely impaired the clearance of myelin debris. Transcriptomic profiling indicated that depletion of Qki impaired total RNA levels and splicing of the genes involved in phagosome formation and maturation. RNA immunoprecipitation (RIP) confirmed the physical interactions between the Qki protein and the mRNAs of Qki targets that are involved in phagocytosis, indicating that Qki regulates their RNA stability. Both Qki depletion and inhibition of Qki target Cd36 greatly reduced the phagocytic activity of microglia and macrophages. The defective uptake and degradation of myelin debris caused by Qki depletion in microglia resulted in unresolved myelin debris that impaired axon integrity, oligodendrocyte maturation, and subsequent remyelination. Thus, our results demonstrate that Qki is an essential regulator of microglia’s phagocytic activity under demyelinating conditions.

13 February 2025 in Cancer Research
Verified
Journal Article
Open access
NHNealia C. House
Nealia C. House
VBVictoria E. Brown
Victoria E. Brown
MCMaxine Chen
Maxine Chen
LYLiang Yuan
Liang Yuan
SMSydney L. Moore
Sydney L. Moore
KFKerrie L. Faia
Kerrie L. Faia
BLU-222 is an investigational, potent, highly selective, orally bioavailable cyclin-dependent kinase 2 (CDK2) inhibitor in clinical development. BLU-222 demonstrated robust antitumor activity in select CCNE1-high ovarian and endometrial cancer models. We used a combination of CRISPR whole-genome screens coupled with targeted genetic and pharmacologic approaches in ovarian and endometrial cell lines to identify biological determinants to predict BLU-222 monotherapy activity. Rb and p16 expression were biomarkers that enriched for CDK2-dependency/BLU-222 sensitivity in CCNE1-overexpressed, nonamplified cells. Furthermore, intact Rb and low p16 expression predicted a BLU-222 and CDK4/6 inhibitor combination response. BLU-222 demonstrated robust activity in combination with carboplatin or paclitaxel in CCNE1-aberrant models, rendering chemotherapy-resistant tumors strongly sensitive to the combination. These findings demonstrate that response to CDK2 inhibition by BLU-222 can be further predicted using a combinatorial biomarker signature that could refine patient selection criteria in CCNE1-high patients and support clinical development. Significance: The identification of biomarkers of response to the CDK2-selective inhibitor BLU-222 and effective combinations with CDK4/6 inhibitors or chemotherapy could enable precision medicine strategies for CDK2 inhibition in ovarian and endometrial cancer. See related article by Dommer and colleagues, p. 1310


3 April 2025
Verified
Other
Open access
NHNealia C. House
Nealia C. House
VBVictoria E. Brown
Victoria E. Brown
MCMaxine Chen
Maxine Chen
LYLiang Yuan
Liang Yuan
SMSydney L. Moore
Sydney L. Moore
KFKerrie L. Faia
Kerrie L. Faia
Evaluation of CDK2-dependency in cell lines using CCLE/DepMap.

3 April 2025
Verified
Other
Open access
NHNealia C. House
Nealia C. House
VBVictoria E. Brown
Victoria E. Brown
MCMaxine Chen
Maxine Chen
LYLiang Yuan
Liang Yuan
SMSydney L. Moore
Sydney L. Moore
KFKerrie L. Faia
Kerrie L. Faia
In vitro BLU-222 + carboplatin and BLU-222 + paclitaxel ZIP synergy plots.

3 April 2025
Verified
Other
Open access
NHNealia C. House
Nealia C. House
VBVictoria E. Brown
Victoria E. Brown
MCMaxine Chen
Maxine Chen
LYLiang Yuan
Liang Yuan
SMSydney L. Moore
Sydney L. Moore
KFKerrie L. Faia
Kerrie L. Faia
BLU-222 antiproliferative effect is mediated by CDK2-RB-E2F axis.